BLUE - Multiplikator Forward P/S bluebird bio, Inc.

Lambang korporat lan logo bluebird bio, Inc. (BLUE)

bluebird bio, Inc. (BLUE) is expanding access to gene therapy through partnerships with insurance companies and clinics. This P/S trend chart reflects fundamental stability, where 0.50 becomes the new value for this metric. The company's developments aim to replace lifelong treatment for rare blood pathologies. However, a critical liquidity shortage and a single-product profile necessitate an urgent update to the sales strategy.

BLUE bluebird bio Inc.: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 07.06.2025

Rincian analitis perusahaan bluebird bio, Inc.

- rega saiki lan proyeksi nilai saham:
Pambiji fundamental perusahaan:bluebird bio, Inc BLUE
Sampel barang bluebird bio, Inc.

This ratio determines the market value of the business relative to projected revenue, allowing investors to assess the premium paid for future cash flows. Analyzing the expected P/S of bluebird bio, Inc. (BLUE) reveals a compression of the multiple, which, given the company's development cycle independent of macroeconomic trends, transforms the asset into an undervalued defensive tool with resilient internal demand.

Pesaing bluebird bio, Inc. (BLUE)

Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|SRPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TWST (Twist Bioscience Inc)|Rasio kapitalisasi marang dodolan sing dikarepake 10x Genomics Corp (TXG)|intelliatx.com - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke STOK|biolifesolutions.com (BLFS) - Rasio rega marang prakiraan pendapatan|WVE - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan MAZE|Multiplikator forward rega marang pendapatan Sionna Therapeutics, Inc. (SION)|Multiplikator forward rega marang pendapatan PRME (Prime Medicine Bio)|Rasio kapitalisasi marang dodolan sing dikarepake Taysha|uniQure Pharma - Multiplikator forward rega marang pendapatan|MeiraGTx Holdings plc - Rasio rega marang prakiraan pendapatan|regenxbio.com - Multiplikator Forward P/S|Solid Bio (SLDB) - Multiplikator forward rega marang pendapatan|OCGN: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan DSGN (Design Therapeutics)|Multiplikator Forward P/S RCKT|Rasio rega marang prakiraan pendapatan FDMT (4D Molecular Therapeutics Inc)|Multiplikator Forward P/S LXEO (Lexeo Therapeutics Inc.)|Rega forward marang dodolan KRRO|EDIT - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Silence Therapeutics SLN|ProQR Therapeutics NV (PRQR) - Rasio rega marang prakiraan pendapatan|Codexis Inc - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Sangamo BioSciences|Kapitalisasi marang prakiraan pendapatan NAUT (Nautilus Biotechnology)|Rasio rega marang prakiraan pendapatan metagenomi.co (MGX)|DTIL: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Generation Bio Co. GBIO|BOLD: Kapitalisasi marang prakiraan pendapatan|XCUR: Multiplikator forward rega marang pendapatan|Imunon (IMNN) - Multiplikator forward rega marang pendapatan|PHIO (RXi Pharmaceuticals) - Multiplikator forward rega marang pendapatan|MBIO (Mustang Bio Inc) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan TransCode Therapeutics, Inc.|Multiplikator Forward P/S bionanogenomics.com|Multiplikator Forward P/S APDN|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.